Subtype
Pancreatic Neuroendocrine Neoplasm
CI-CAN-00001357Explore in graph →
Non-malignant36 active trials1 evidence items
- NCIt
- C27031
Loading cancer entity…
Subtype
CI-CAN-00001357Explore in graph →
Clinical trials
175 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02125929 | Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms | completed | N/A | 156 | Peking Union Medical College HospitalOTHER | 1 | Aug 6, 2015 | clinicaltrials |
| NCT02400996 | An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms | completed | — | 40 | Medical College and Hospital KolkataOTHER | 0 | Apr 29, 2015 | clinicaltrials |
| NCT00937079 | Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients | completed | — | 30 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jan 9, 2015 | clinicaltrials |
| NCT00131911 | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT01121562 | Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 12 | PfizerINDUSTRY | 1 | Jun 30, 2014 | clinicaltrials |
| NCT00942682 | Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2014 | clinicaltrials |
| NCT02121366 | EUS-guided Ethanol Ablation of an Insulinoma(EUS) | unknown | N/A | 50 | Guangxi Medical UniversityOTHER | 1 | Apr 23, 2014 | clinicaltrials |
| NCT01381822 | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors(TH-CR-410) | unknown | Phase 1 | 58 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 21, 2014 | clinicaltrials |
| NCT02038738 | 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | unknown | Phase 1 / Phase 2 | 250 | Ochsner Health SystemOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT00454376 | Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors | unknown | — | 408 | National Cancer Institute (NCI)NIH | 10 | Oct 29, 2013 | clinicaltrials |
| NCT00602082 | Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 84 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Aug 7, 2013 | clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00027638 | Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2013 | clinicaltrials |
| NCT00075439 | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00363051 | Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | completed | Phase 2 | 160 | Novartis PharmaceuticalsINDUSTRY | 11 | May 10, 2013 | clinicaltrials |
| NCT00006368 | Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 1 | May 1, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00017199 | PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 2 | — | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00434109 | Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | completed | Phase 2 | 39 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 14, 2012 | clinicaltrials |
| NCT00466856 | Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors | terminated | Phase 2 | 10 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 18, 2012 | clinicaltrials |
| NCT00019786 | Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases | completed | Phase 2 | 67 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 23, 2012 | clinicaltrials |
| NCT00428597 | A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors | terminated | Phase 3 | 171 | PfizerINDUSTRY | 11 | Oct 11, 2010 | clinicaltrials |
| NCT00005910 | Laparoscopy to Remove Pancreatic Tumors (Insulinomas) | completed | N/A | 23 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Aug 6, 2015source: clinicaltrials